The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Gamma secretase inhibitors of Notch signaling
Open accessAbstract
The numerous processes involved in the etiology of breast cancer such as cell survival, metabolism, proliferation, differentiation, and angiogenesis are currently being elucidated. However, underlying mechanisms that drive breast cancer progression and drug resistance are still poorly understood. As we discuss here in detail, the Notch signaling pathway is an important regulatory component of normal breast development, cell fate of normal breast stem cells, and proliferation and survival of breast cancer initiating cells. Notch exerts a wide range of critical effects through a canonical pathway where it is expressed as a type I membrane precursor heterodimer followed by at least two subsequent cleavages induced by ligand engagement to ultimately release an intracellular form to function as a transcriptional activator. Notch and its ligands are overexpressed in breast cancer, and one method of effectively blocking Notch activity is preventing its cleavage at the cell surface with γ-secretase inhibitors. In the context of Notch signaling, the application of clinically relevant anti-Notch drugs in treatment regimens may contribute to novel therapeutic interventions and promote more effective clinical response in women with breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone acetylation and transcriptional regulatory mechanisms
Struhl, K. (1998) · Genes & Development · doi:10.1101/gad.12.5.599 · Cited by 1,815 · cited 1×
“γ-secretase severs NICD from the inside of the cell membrane, allowing it to enter the cytoplasm(37) and eventually translocate to the nucleus (Figure 2).(38)”
Liver: An organ with predominant innate immunity
Gao, B., Jeong, W.-I., & Tian, Z. (2008) · Hepatology · doi:10.1002/hep.22034 · Cited by 952
Cited by
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
Krishnamurthy, N., & Kurzrock, R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.002 · Cited by 1,026
Targeting Notch signaling pathway in cancer: Clinical development advances and challenges
Takebe, N., Nguyen, D., & Yang, S. X. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.005 · Cited by 413
Wang, Y., Gunasekara, D. B., Reed, M. I., DiSalvo, M., Bultman, S. J., Sims, C. E., Magness, S. T., & Allbritton, N. L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.03.005 · Cited by 373
Gonzalez-King, H., García, N. A., Ontoria-Oviedo, I., Ciria, M., Montero, J. A., & Sepúlveda, P. (2017) · Stem Cells · doi:10.1002/stem.2618 · Cited by 352
Upreti, M., Jyoti, A., Johnson, S. E., Swindell, E. P., Napier, D., Sethi, P., Chan, R., Feddock, J. M., Weiss, H. L., O’Halloran, T. V., et al. (2106) · Oncotarget · doi:10.18632/oncotarget.9490 · Cited by 21
“An improved understanding of the biology of TNBC has led to the discovery of therapeutic targets for TNBC, such as the Notch signaling pathway (RO-4929097) [10], Wnt/b-catenin pathway (Salinomycin) [11], DNA repair pathways (PARP1 inhibitors: Iniparib, Olaparib) [12, 13], Overexpressed epidermal growth factor (EGFR in…”
Background
Metadata
- Authors
- Osipo, C., Zlobin, & Olsauskas-Kuprys
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2013-07
- Volume
- 6
- Pages
- 943
- ISSN
- 1178-6930 (ISSN-L)
- OpenAlex
- W2034009919
- Cited by
- 174
- References
- 2
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.